Is Triptorelin Legit? Evidence Grade and Plain-English Verdict
Triptorelin is rated Level A. The short verdict: Triptorelin (Trelstar) is FDA-approved for prostate cancer androgen deprivation and gender-affirming hormone therapy, with multiple Phase 3 RCTs supporting both indications. As a GnRH agonist, it produces reliable castrate-level testosterone suppression with a well-characterized adverse effect profile. For research into GnRH agonist pharmacology or testosterone suppression, it is a validated reference compound.
Direct Answer
Triptorelin (Trelstar) is FDA-approved for prostate cancer androgen deprivation and gender-affirming hormone therapy, with multiple Phase 3 RCTs supporting both indications. As a GnRH agonist, it produces reliable castrate-level testosterone suppression with a well-characterized adverse effect profile. For research into GnRH agonist pharmacology or testosterone suppression, it is a validated reference compound.
- Evidence grade
- Level A
- Research status
- FDA Approved
- Category
- Sexual Health
- Best for
- Prostate cancer androgen deprivation, gender-affirming hormone therapy, GnRH agonist pharmacology
Why the Claim Is Strong or Weak
Triptorelin is a synthetic GnRH agonist used to treat prostate cancer, endometriosis, uterine fibroids, and central precocious puberty. After an initial stimulatory phase, continuous administration downregulates GnRH receptors, effectively suppressing sex hormone production.
As of April 2026, 6 new paper(s) published in PubMed including: Optimization of Triptorelin Administration in Children With Central Precocious Puberty and Short Stature; Efficacy of 24-Weekly Versus 12-Weekly Decapeptyl SR Treatment in Central Precocious Puberty.
Top Evidence Signals
- Prostate Cancer Control: Level A, includes human evidence - Triptorelin achieves castrate testosterone levels in >95% of advanced prostate cancer patients. Multiple large RCTs demonstrate disease control equivalent to surgical castration with reversibility.
- Endometriosis Symptom Relief: Level A, includes human evidence - Significant reduction in endometriosis-related pain, dysmenorrhea, and endometrial implant size. Efficacy comparable to other GnRH agonists with estrogen suppression.
- Central Precocious Puberty Arrest: Level A, includes human evidence - Effectively halts premature pubertal development and preserves adult height potential. Standard of care for central precocious puberty in children.
Where Claims Usually Overreach
- Initial testosterone flare can worsen prostate cancer symptoms - consider anti-androgen cover for first 2-4 weeks
- Long-term use causes significant bone loss - monitor BMD and consider add-back therapy
- Cardiovascular risk may be increased with androgen deprivation therapy
- Hyperglycemia and diabetes risk elevated in prostate cancer patients on ADT
Primary Sources
- Triptorelin 6-month depot for the treatment of advanced prostate cancer. European Urology, 2009.
- GnRH agonists in the treatment of endometriosis: a Cochrane review. Cochrane Database of Systematic Reviews, 2010.
- Triptorelin for central precocious puberty: efficacy and safety. Journal of Clinical Endocrinology & Metabolism, 2004.
Evidence Snapshot
| Evidence grade | Level A |
|---|---|
| Research status | FDA Approved |
| Best supported outcomes | Prostate Cancer Control (Level A), Endometriosis Symptom Relief (Level A), and Central Precocious Puberty Arrest (Level A) |
| Primary citation count | 3 |
| Last reviewed | 2026-04-04 |
Related Guides
How to Cite This Page
ExaminePeptides. "Is Triptorelin Legit? Evidence Grade and Plain-English Verdict." Last reviewed 2026-04-04. https://examinepeptides.com/answers/is-triptorelin-legit/
This static answer page is built for fast indexing and direct citation. It summarizes the matching full evidence review and links back to primary sources where the source database includes them.